CAMBRIDGE, Mass., April 8, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting preclinical data from its two most advanced anti-cancer programs during the 2009 American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado from April 18 through April 22, 2009. The anti-cancer programs for which Infinity will be presenting data include its potential first-in-class heat shock protein 90 (Hsp90) inhibitor program, and its Hedgehog signaling pathway inhibitor program that targets smoothened.
